戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 synthesis of a triene-containing C17-benzene ansamycin.
2  of structural derivatives (6-9) of phenolic ansamycins.
3 e the preparation of potent non-benzoquinone ansamycins.
4 compared with the corresponding benzoquinone ansamycins.
5 synthetic precursor of rifamycin and related ansamycins, a series of target-directed mutations and he
6  have suggested that the in vitro potency of ansamycins against Hsp90 may be enhanced in the presence
7 hydroxybenzoic acid (AHBA), precursor of the ansamycin and mitomycin antibiotics, proceeds by the ami
8 ibition of Akt activation is achievable with ansamycins and may be useful for the treatment of HER2 d
9 e quinone chromophores of the naphthoquinone ansamycins and related natural products.
10 cins are metabolized by NQO1 to hydroquinone ansamycins and that Hsp90-mediated trans-cis isomerizati
11 s- and cis-amide isomers of the benzoquinone ansamycins and their mechanism of Hsp90 inhibition.
12                                          The ansamycin antibiotic geldanamycin (GA) induces the intra
13 sent studies demonstrate that treatment with ansamycin antibiotic geldanamycin (GA), or its less toxi
14                                          The ansamycin antibiotic geldanamycin has frequently been us
15 ibited hypersensitivity to the Hsp90-binding ansamycin antibiotic geldanamycin.
16 ino)-17-demethoxygeldanamycin (17-AAG) is an ansamycin antibiotic that binds to a conserved pocket in
17          Geldanamycin (GA) is a benzoquinone ansamycin antibiotic that disrupts Hsp90-protein interac
18 eatment of MCF-7 cells with geldanamycin, an ansamycin antibiotic that inhibits Hsp90 function, MLK3
19              We evaluated the use of another ansamycin antibiotic, rifamycin SV MMX (AEMCOLO) in the
20 methoxygeldanamycin (17-AAG), a benzoquinoid ansamycin antibiotic, which binds to heat shock protein
21 h two additional AHBA synthases from related ansamycin antibiotic-producing microorganisms.
22 maturation of Hsp90 target proteins and that ansamycin antibiotics abrogate the activity of such prot
23         This approach yields new benzoxazole ansamycin antibiotics and enables their functionalizatio
24         The recent discovery that a class of ansamycin antibiotics bind specifically to Hsp90 allowed
25 -dependent processes to ansamycin treatment, ansamycin antibiotics disrupt signaling through some mec
26 complexes in cell lysates, and Hsp90-binding ansamycin antibiotics disrupt the activity of Hsp90-depe
27            In this study, I demonstrate that ansamycin antibiotics disrupt the function of Hsp90 targ
28                         Targeting HSP90 with ansamycin antibiotics disrupts the normal processing of
29                                              Ansamycin antibiotics inhibit function of the heat shock
30 ological intercession of Hsp90 activity with ansamycin antibiotics or depletion of BAG3 by small inte
31                             Hsp90 inhibitory ansamycin antibiotics such as geldanamycin (GA) induce r
32 amino)-17-demethoxygeldanamycin (17-AAG) are ansamycin antibiotics that bind to a highly conserved po
33 cking Sba1 displays increased sensitivity to ansamycin antibiotics, and this phenotype is rescued by
34             The polyketide chains of the two ansamycin antibiotics, ansatrienin (mycotrienin) and nap
35  E (1), member of a novel class of cytotoxic ansamycin antibiotics, has been achieved.
36                                          The ansamycin antibiotics, herbimycin A (HA) and geldanamyci
37                          The biosynthesis of ansamycin antibiotics, like rifamycin B, involves format
38                                              Ansamycin antibiotics, such as 17-allylaminogeldanamycin
39                                              Ansamycin antibiotics, such as geldanamycin, potently in
40 tiosum, the producer of the highly cytotoxic ansamycin antibiotics, the ansamitocins.
41 that some of the effects of 17-AAG and other ansamycins are due to their effects on VDAC and that thi
42  rather than cis-amide forms of benzoquinone ansamycins are metabolized by NQO1 to hydroquinone ansam
43                           These benzoquinone ansamycins are potent inhibitors of Hsp90 function, whic
44 uch attention is focused on the benzoquinone ansamycins as anticancer agents, with several derivative
45                               Benzoquinonoid ansamycins (BAs) have recently been shown to specificall
46 redicted to be involved in the production of ansamycin, benzoisochromanequinone, streptogramin using
47                           Geldanamycin is an ansamycin benzoquinone, and we show here that it causes
48        Cross-resistance was found with other ansamycin benzoquinones but not with the structurally un
49 sent evidence that the approximately 100-kDa ansamycin-binding protein is GRP94.
50 DDP-induced signaling pathways revealed that ansamycins block the activation of mitogen-activated pro
51 neurodegenerative diseases, and benzoquinone ansamycin (BQA) Hsp90 inhibitors such as geldanamycin (G
52                             The benzoquinone ansamycins (BQAs) are a valuable class of antitumor agen
53 the reduction of this series of benzoquinone ansamycins by NQO1 generates the corresponding hydroquin
54          The reduction of these benzoquinone ansamycins by recombinant human NQO1 to the correspondin
55                                              Ansamycins cause RB-dependent G1 arrest that is associat
56                                              Ansamycins caused rapid degradation of HER2 and a concom
57              Rifaximin, an antibiotic of the ansamycin class has been shown to be effective in the tr
58 bition after treatment with the benzoquinone ansamycins compared with the MDA468 cells; this increase
59                      We found that while the ansamycin compounds have the commonly observed negative
60  investigation of binding of nucleotides and ansamycin compounds to this domain.
61                         The reduction of the ansamycin core enables an increase in anticancer potency
62 ot the cis-amide isomers of the benzoquinone ansamycins could be accommodated by the NQO1 active site
63 spite structural studies on the complexes of ansamycin derivatives with the ATPase domain of Hsp90, c
64                           Thus, benzoquinone ansamycin drugs and their derivatives, such as 17-allyl-
65 s- and cis-amide isomers of the hydroquinone ansamycins exhibited increased binding affinity for Hsp9
66       The increased duration of benzoquinone ansamycin exposure showed increased potency and -fold in
67 cer cells and is inhibited by members of the ansamycin family of antibiotics.
68                                          The ansamycin family of natural products and their derivativ
69                             The benzoquinone ansamycin geldanamycin (GA) binds to HSP90 and disrupts
70                One of them, the benzoquinone ansamycin geldanamycin (GA) Mr-90,000 heat-shock protein
71          Therefore, we hypothesized that the ansamycin geldanamycin and its 17-allylamino-17-demethox
72                             The benzoquinone ansamycin geldanamycin and its derivatives are inhibitor
73 bes the influential role of the benzoquinone ansamycin geldanamycin and the resorcylic acid macrolact
74            Cotreatment with the benzoquinone ansamycin Geldanamycin depleted Raf-1 but did not decrea
75 r PC-3 and LNCaP cells with the benzoquinone ansamycin geldanamycin, an Hsp90-specific inhibitor, ind
76                             The benzoquinoid ansamycins geldanamycin (GA), herbimycin, and their deri
77 t extracts was inhibited by the benzoquinoid ansamycins geldanamycin and macbecin.
78                     ADP and the benzoquinone ansamycin, geldanamycin, are potent inhibitors of comple
79 eatment of tumor cells with the benzoquinone ansamycin, geldanamycin, leading to a marked reduction i
80 breast carcinoma cells with the benzoquinoid ansamycin, geldanamycin, rapidly depletes p185c-erbB-2 p
81                                          The ansamycins, geldanamycin (GA) and its derivative, 17-all
82 0 ATPase activity including the benzoquinone ansamycins, geldanamycin and 17-allylamino-17-demethoxyg
83  trans-cis isomerization of the benzoquinone ansamycins in Hsp90 inhibition has been disputed in rece
84 mulation of the high-affinity dihydroquinone ansamycins in tumor cells contributes to the antitumor a
85 tive effects of geldanamycin, a benzoquinone ansamycin, in HT22 cells were associated with a down-reg
86             This mechanism also explains the ansamycin-induced proteolysis of several protooncogenic
87                                          The ansamycins inhibit refolding, both in vivo and in a cell
88                             The benzoquinone ansamycins inhibit the ATPase activity of the 90-kDa hea
89                                          The ansamycins inhibited DDP-induced activation of caspases
90                                              Ansamycin inhibition of chaperone-dependent activity inc
91 s- and cis-amide isomers of the benzoquinone ansamycins into the open Hsp90 structure.
92                                              Ansamycin natural products and selected structural analo
93               Four cyclopentenone-containing ansamycin polyketides (mccrearamycins A-D), and six new
94                                              Ansamycins reduced to their dihydroquinones in the prese
95 ating increased efficacy of the hydroquinone ansamycin relative to its parent quinone.
96 ks chemical and structural similarity to the ansamycin rifampicin (Rif), an RNAP inhibitor widely use
97 tions with the C-12 methoxy group of the GdA ansamycin ring.
98 7-allylamino portion of 17AAG and not on its ansamycin ring.
99                                          The ansamycins shift the mode of Hsp90 from refolding to deg
100                                              Ansamycins such as rifamycin, ansamitocin, and geldanamy
101   Treatment of SKBr3 cells with benzoquinone ansamycins, such as geldanamycin (GA), depletes p185erbB
102                 Geldanamycin, a benzoquinone ansamycin that binds to animal hsp90s and prevents their
103  Sf9 cells with geldanamycin, a benzoquinone ansamycin that binds to hsp90 and disrupts its function,
104 of L cells with geldanamycin, a benzoquinone ansamycin that binds to hsp90 and disrupts its function,
105          Geldanamycin (GD) is a benzoquinone ansamycin that inhibits the function of Hsp90.
106  when this function is interfered with by an ansamycin, there is a further shift to proteolytic degra
107  sensitivity of Hsp90-dependent processes to ansamycin treatment, ansamycin antibiotics disrupt signa
108            The triene-containing C17-benzene ansamycins trienomycins A and F were prepared in 16 step
109 g a fundamentally new route to shikimate and ansamycin-type compounds, this result enables further ge
110 fied human Hsp90 by a series of benzoquinone ansamycins was examined in the presence and absence of N
111 human NQO1 to the corresponding hydroquinone ansamycins was monitored by high-performance liquid chro
112 , and HPLC analysis showed that hydroquinone ansamycins were formed by the MDA468/NQ16 cells, which c
113 bitor of NQO1, showing that the hydroquinone ansamycins were more potent Hsp90 inhibitors than their
114 C inhibitor, or geldanamycin, a benzoquinone ansamycin, which destabilizes and depletes Raf-1, marked
115 QO1 generates the corresponding hydroquinone ansamycins, which exhibit enhanced Hsp90 inhibition.
116 xtensive study with a series of benzoquinone ansamycins, which includes gel-danamycin, 17-(amino)-17-
117 cts between yeast Hsp90 and the hydroquinone ansamycins, which translated to greater interaction ener
118 teraction of rifabutin (RFB), a naphthalenic ansamycin, with membrane models.

 
Page Top